Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Analytical, CMC and Specification Consultant for Pharmaceutical Drug Substance and Drug Product Development

Technical Consultant #1620


  • Assessing specification and CMC analytical development for pharmaceutical drug substances and drug products.
  • Analytical project planning and strategies for early, mid and late stage development programs.
  • Writing, editing, and reviewing analytical technical reports.
  • CMC and regulatory submission documents for Health Authority and FDA responses.
  • HPLC method development, validation and transfer.
  • Subject matter expert for the isolation and identification of synthetic impurities and degradation product unknowns.
  • Contract Research Organization (CRO) management.
  • Analytical Investigations.
  • Due diligence preparations.
  • Analytical life cycle product support; competitor analysis.
  • Improving Analytical Partnerships - organizational development.


Independent Consultant-Present

Schering-Plough Research Institute, Summit, NJ, Senior Principal Scientist, 1989 - 2009

  • Leadership of global analytical teams supporting drug substances and drug products in development (toxicological drug substance release through NDA post-submission support).
  • Managed and developed groups of up to 9 scientists in both research and GMP environments. Managed CRO relationships.
  • Proposed broad analytical strategies and executed specific tactical plans for drug substance and drug product analysis, excipients, equipment cleaning, dissolution testing, physical-chemical analysis, and microbiological analytical inputs.
  • Key CMC author for regulatory submissions using the common technical document (CTD) format.
  • Led a thrombin receptor antagonist analytical program from Phase I to Phase III.
  • Served as Analytical Team Leader for the reformulation of temozolomide capsules.
  • Led the analytical program for a priority CNS compound from pre-Tox to Phase I.
  • Led global matrixed analytical teams, with partners in Puerto Rico, Ireland, Finland, Switzerland, Belgium, Singapore, and Japan.
  • Developed and validated test methods following ICH Guidelines.
  • Supported drug substance and product development. Quantified impurities, degradation products, and potentially genotoxic compounds.
  • Assured critical quality attributes, and chemical, physical, and performance stability.
  • Applied advanced expertise in HPLC method development, achieved difficult chiral and isomeric separations.
  • Leveraged specialized stationary phases, alternate detection modes, and LC-MS to overcome scientific challenges and to isolate and identify chromatographic unknowns.
  • Subject matter expert for the isolation and identification of synthetic impurity and degradation product unknowns.
  • Responded rapidly to health authority and FDA regulatory questions.
  • Proposed, justified, and implemented drug substance and drug product specifications.
  • Analytical subject matter expert for FDA meetings, and SME for due diligence evaluations.
  • Authored approved CMC content for: Elocon Cream, Claritin-D 12 Hour Tablets, Azium Powder, Azium Solution, Claritin Syrup, Clarinex-D 24 Hour Tablets and Temodar Capsules.
  • Co-validated registration drug substance testing methods with the commercial manufacturing site saving time and technology transfer costs.
  • Thorough knowledge of GMPs and quality systems for drug substance and drug product testing.
  • Discovered and implemented three novel analytical techniques including a simple performance test of petrolatum to predict the potential for future ointment bleeding.
  • Implemented efficiency initiatives including automated sample preparations, partnered QbD product development, UPLC applications and simplified testing of process ranging samples.
  • Championed Consent Decree culture change by drafting and revising SOPs and participating in several important process re-engineering projects.
  • Co-authored two training modules (isolation and identification of unknowns; and, specification development) for a CMC Fundamentals training course designed to develop junior staff in the pharmaceutical sciences.

Purdue Frederick Research Center, Yonkers, NY, Research Scientist, 1987 - 1989

  • Developed and validated HPLC and dissolution methods supporting product development, and release and stability testing.
  • Created a Reference Standard system and standardized formatting of test methods.

Warner-Lambert, Lititz, PA, Associate Analyst, 1984 - 1987

  • Tested excipients, intermediate materials, pharmaceuticals, consumer health products, and stability samples in the QC laboratory. Backup LIMS System Manager.

Honors & Publications

Academic and Professional Affiliations

  • American Association of Pharmaceutical Scientists
  • North Jersey Chromatography Group
  • Chromatography Forum of Delaware Valley - Life Member


  • Finalist for the Desty Award for Innovation in Separation Science


  • 17 publications, posters, and presentations


  • M.S. Industrial Pharmacy, Long Island University, Brooklyn, NY
  • B.S. Chemistry, Juniata College, Huntingdon, PA
Back to Search Result GO